2QK Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Scholar Rock Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.40 |
| 52 Week High | US$46.00 |
| 52 Week Low | US$6.15 |
| Beta | 0.38 |
| 1 Month Change | 0.76% |
| 3 Month Change | -25.00% |
| 1 Year Change | 135.71% |
| 3 Year Change | 452.30% |
| 5 Year Change | 56.21% |
| Change since IPO | 180.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.3% | -0.5% | 1.1% |
| 1Y | 135.7% | -13.0% | 16.0% |
Return vs Industry: 2QK exceeded the German Biotechs industry which returned -13.5% over the past year.
Return vs Market: 2QK exceeded the German Market which returned 15% over the past year.
Price Volatility
| 2QK volatility | |
|---|---|
| 2QK Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 2QK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2QK's weekly volatility has decreased from 52% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 128 | David Hallal | www.scholarrock.com |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Scholar Rock Holding Corporation Fundamentals Summary
| 2QK fundamental statistics | |
|---|---|
| Market cap | €2.54b |
| Earnings (TTM) | -€234.18m |
| Revenue (TTM) | n/a |
Is 2QK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$190.13m |
| Gross Profit | -US$190.13m |
| Other Expenses | US$74.03m |
| Earnings | -US$264.16m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.78 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 15.9% |
How did 2QK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 17:25 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scholar Rock Holding Corporation is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Etzer Darout | BMO Capital Markets Equity Research |
| Guyn Kim | BMO Capital Markets Equity Research |